免疫检查点阻断剂在 III 期黑色素瘤患者辅助治疗中引起的迟发性毒性。 - Suppr

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.

作者信息

Mandalà Mario, Merelli Barbara, Indriolo Amedeo, Tondini Carlo

机构信息

Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

出版信息

Eur J Cancer. 2018 May;95:130-132. doi: 10.1016/j.ejca.2018.02.019. Epub 2018 Mar 17.

DOI:10.1016/j.ejca.2018.02.019

PMID:29559189

Abstract

摘要

相似文献

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.

Eur J Cancer. 2018 May;95:130-132. doi: 10.1016/j.ejca.2018.02.019. Epub 2018 Mar 17.

Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.

Expert Opin Biol Ther. 2018 Jul;18(sup1):77-83. doi: 10.1080/14712598.2018.1494717.

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20.

Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.

Melanoma Res. 2017 Oct;27(5):524-525. doi: 10.1097/CMR.0000000000000384.

The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

Eur J Cancer. 2017 Nov;86:101-105. doi: 10.1016/j.ejca.2017.09.014. Epub 2017 Sep 29.

Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.

Eur J Dermatol. 2018 Feb 1;28(1):129-130. doi: 10.1684/ejd.2017.3192.

Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.

J Dermatol. 2018 Oct;45(10):e287-e289. doi: 10.1111/1346-8138.14325. Epub 2018 Apr 14.

Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.

Melanoma Res. 2017 Apr;27(2):171-173. doi: 10.1097/CMR.0000000000000335.

Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.

Clin Exp Dermatol. 2018 Jun;43(4):497-499. doi: 10.1111/ced.13399. Epub 2018 Feb 3.

Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.

Melanoma Res. 2016 Aug;26(4):417-20. doi: 10.1097/CMR.0000000000000261.

引用本文的文献

Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review.

BMC Pulm Med. 2024 Dec 2;24(1):597. doi: 10.1186/s12890-024-03424-9.

Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase.

J Immunother Cancer. 2024 Nov 3;12(11):e009902. doi: 10.1136/jitc-2024-009902.

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.

Curr Oncol. 2024 Oct 18;31(10):6356-6383. doi: 10.3390/curroncol31100473.

Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.

Mol Cancer. 2023 Apr 13;22(1):70. doi: 10.1186/s12943-023-01772-4.

Late‑onset immune checkpoint inhibitor‑related pneumonitis after cessation of sintilimab: A case report and literature review.

Exp Ther Med. 2023 Jan 3;25(2):83. doi: 10.3892/etm.2023.11782. eCollection 2023 Feb.

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review.

Front Immunol. 2023 Jan 10;13:1072612. doi: 10.3389/fimmu.2022.1072612. eCollection 2022.

Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.

Front Immunol. 2022 Jul 28;13:898811. doi: 10.3389/fimmu.2022.898811. eCollection 2022.

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.

Front Immunol. 2021 May 28;12:663986. doi: 10.3389/fimmu.2021.663986. eCollection 2021.

Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.

Curr Oncol. 2020 Apr;27(Suppl 2):S43-S50. doi: 10.3747/co.27.5111. Epub 2020 Apr 1.

Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon.

Oncologist. 2020 May;25(5):e753-e757. doi: 10.1634/theoncologist.2019-0666. Epub 2020 Mar 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献